An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa
Benjamin Vesin, Jodie Lopez, Amandine Noirat, Pierre Authié, Ingrid Fert, Fabien Le Chevalier, Fanny Moncoq, Kirill Nemirov, Catherine Blanc, Cyril Planchais, Hugo Mouquet, Françoise Guinet, David Hardy, Francina Langa Vives, Christiane Gerke, François Anna, Maryline Bourgine, Laleh Majlessi, Pierre Charneau
Topics & Concepts
VirologyImmunityNasal administrationBiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)LungImmunologyMucosal immunityCoronavirus disease 2019 (COVID-19)MedicineImmune systemInfectious disease (medical specialty)DiseasePathologyInternal medicineSARS-CoV-2 and COVID-19 ResearchBacterial Infections and VaccinesImmunotherapy and Immune Responses